Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · Real-Time Price · USD
30.00
+0.18 (0.60%)
Jun 15, 2026, 4:00 PM EDT - Market closed
Stoke Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 155.66 | 84.71 | 128.06 | 191.44 | 113.56 | 144.9 |
Short-Term Investments | 187.89 | 200.45 | 88.92 | 9.95 | 116.04 | 74.92 |
Cash & Short-Term Investments | 343.55 | 285.16 | 216.97 | 201.39 | 229.6 | 219.81 |
Cash Growth | -3.88% | 31.43% | 7.74% | -12.28% | 4.45% | -23.49% |
Accounts Receivable | 4.45 | 5.94 | 1.67 | - | - | - |
Other Receivables | 1.69 | 1.97 | 0.7 | 0.06 | 0.59 | 0.13 |
Total Trade Receivables | 6.14 | 7.91 | 2.37 | 0.06 | 0.59 | 0.13 |
Other Current Assets | 17 | 12.63 | 13.41 | 13.88 | 13.89 | 9.28 |
Total Current Assets | 366.68 | 305.7 | 232.76 | 215.34 | 244.07 | 229.22 |
Net Property, Plant & Equipment | 5.89 | 6.25 | 8.25 | 12.43 | 11.43 | 9.08 |
Long-Term Investments | 67.48 | 106.26 | 29.82 | - | - | - |
Other Long-Term Assets | 3.23 | 0.23 | 0.72 | 0.57 | 0.57 | 0.57 |
Total Assets | 443.28 | 418.43 | 271.56 | 228.34 | 256.07 | 238.87 |
Accounts Payable | 6.84 | 4.94 | 2.5 | 1.7 | 0.77 | 2.39 |
Accrued Expenses | 23.9 | 41.04 | 18.57 | 13.82 | 15.75 | 14.75 |
Unearned Revenue | 10.07 | 11.9 | 18.99 | 15.31 | 14.88 | - |
Total Current Liabilities | 40.81 | 57.88 | 40.06 | 30.82 | 31.39 | 17.14 |
Other Long-Term Liabilities | 7.59 | 8.1 | 2.48 | 37.96 | 39.82 | 3.95 |
Total Long-Term Liabilities | 7.59 | 8.1 | 2.48 | 37.96 | 39.82 | 3.95 |
Total Liabilities | 48.4 | 65.98 | 42.53 | 68.78 | 71.22 | 21.09 |
Common Stock | 0.01 | 0.01 | 0.01 | 0 | 0 | 0 |
Additional Paid-in Capital | 942.7 | 849.62 | 720 | 561.43 | 483.17 | 414.02 |
Accumulated Other Comprehensive Income | -0.12 | 0.54 | -0.15 | -0.02 | -1.18 | -0.17 |
Retained Earnings | -547.72 | -497.72 | -490.83 | -401.85 | -297.15 | -196.08 |
Shareholders' Equity | 394.88 | 352.46 | 229.02 | 159.57 | 184.85 | 217.78 |
Total Liabilities & Equity | 443.28 | 418.43 | 271.56 | 228.34 | 256.07 | 238.87 |
Net Cash (Debt) | 343.55 | 285.16 | 216.97 | 201.39 | 229.6 | 219.81 |
Net Cash Growth | 20.47% | 31.43% | 7.74% | -12.28% | 4.45% | -23.49% |
Net Cash Per Share | 5.83 | 4.82 | 4.02 | 4.58 | 5.90 | 5.98 |
Book Value | 394.88 | 352.46 | 229.02 | 159.57 | 184.85 | 217.78 |
Book Value Per Share | 6.70 | 5.95 | 4.24 | 3.63 | 4.75 | 5.93 |
Tangible Book Value | 394.88 | 352.46 | 229.02 | 159.57 | 184.85 | 217.78 |
Tangible Book Value Per Share | 6.70 | 5.95 | 4.24 | 3.63 | 4.75 | 5.93 |